Iovance Biotherapeutics Stock Earnings Reports

Iovance reported Q3 2025 progress including 13% quarter-over-quarter revenue growth to roughly $68M (Amtagvi ~$58M; Proleukin ~$10M) and an improved gross margin of ~43% following restructuring and cost-optimization measures. Management announced centralization of all manufacturing to its internal Iovance Cell Therapy Center (iCTC) in early 2026 to lower cost of sales, improve margins and scale capacity. The company reiterated full-year 2025 revenue guidance of $250M–$300M and reported cash of ~$307M, expected to fund operations into Q2 2027. Commercial expansion is focused on broadening adoption of Amtagvi across academic and community Authorized Treatment Centers (ATCs); real-world data show a 60% response rate in second-line melanoma. Interim registrational LUN-202 lung cancer data (n=39) for Lifileucel showed an objective response rate of 26%, disease control rate of 72%, and median duration of response not reached at >25 months — management plans to enroll ~80 patients in 2026 to support an accelerated approval pathway with a potential U.S. launch in H2 2027. International filings/approvals are underway (Canada approved; UK, Australia, Switzerland pending; EU resubmission planned). Company emphasized continued expense discipline, manufacturing quality improvements (write-offs down ~40% since start of year), and efforts to drive profitability. Key risks remain regulatory timelines, enrollment execution, and typical commercial ramp uncertainties.